[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_3435 

# __Limited research on drug efficacy, safety, and antibody response__

## Articles mentionning the risk

* [Abideen_mitigation_2020](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_376.md)

## Mitigations of this risk

* [Invest in research on drug efficacy, safety, and antibody response for improved treatment and immunization strategies](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_5306.md)

## Name of the risk

Risk of ineffective treatment and immunization strategies for disease outbreaks

## People affected by this risk

* [Immunologists](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2655.md)
* [Pharmacologists](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2657.md)
* [Public health researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2658.md)

## Stakeholders who can mitigate this risk

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_413.md)
* [Research institutions](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [And drug screening technologies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1959.md)
* [Clinical trials](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_3948.md)
* [Immunological assays](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_3949.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Lack of effective medical solutions](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_37.md)

